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Abstract 
Background: BRAF is the most frequently mutated gene in differentiated thyroid cancer (DTC). Previous studies on 
DTC have well documented high rates of the BRAFV600E mutation in patients of mixed ages. Previous studies either 
included a mix of pediatric and adult patients or pediatric patients only. However, the prevalence of hotspot and non‑
hotspot BRAF mutations and its significance in pure adult DTCs is not yet well determined. In this study we determine 
the frequency of this classical BRAF mutation and other rare BRAF mutations in pure adult DTCs.
Methods: A total of 204 adult DTC samples (Age >18 years) were analyzed for mutations in exon 15 of the BRAF 
gene by performing polymerase chain reaction (PCR) amplification of tumor genomic DNAs and direct sequencing 
of amplicons using Sanger sequencing. Obtained results were correlated to clinical and pathological characteristics of 
DTCs. Statistical analyses were performed using SPSS (The Statistical Package for Social Sciences) version 20 software.
Results: Overall, BRAF mutations were identified in 48.5 % (99/204) of adult DTCs. Three rare non‑hotspot mutations 
(T599I, T599dup and K601E) were detected in four tumor samples (2 %). One (K601E) of these non‑hotspot mutations 
occurred in conventional papillary thyroid cancer (CPTC) and other three (T599I, T599dup and K601E) were found in 
follicular variant PTC. We found significant association between BRAFV600E mutation and age (P < 0.0001), extrathyroi‑
dal invasion (P = 0.017), lymph node metastasis (P = 0.038) and TNM stage III/IV (P = 0.001).
Conclusions: Our study is the first to report BRAF mutations in a pure adult sample of DTCs of Saudi Arabian ethnic‑
ity. Our results show a high rate and a strong prognostic role of the classical BRAFV600E mutation and also suggest a 
common occurrence of non‑hot spot mutations in adult DTC from this highly inbred population.
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Background
Thyroid cancer is the most common malignant endo-
crine tumor. Its incidence has been considerably increas-
ing over the last 4 decades [1, 2]. Thyroid cancer usually 
arises from follicular epithelial cell or parafollicular cells 
[3]. The latter is the cell of origin of medullary thyroid 
cancer [3]. Follicular cell-derived thyroid cancer is by 
far the most common type (95 %) and is classified to dif-
ferentiated thyroid cancer (DTC), poorly differentiated 
(PDTC) and undifferentiated (anaplastic) subtypes [3]. 
DTC is further classified to papillary thyroid cancer 
(PTC) and follicular thyroid cancer (FTC) [28]. In Saudi 
Arabia, DTC is the fourth most common type of can-
cer in general and the second most common cancer in 
women [4]. Over the last decade, there has been a signifi-
cant progress in our understanding of DTC pathogenesis 
[5]. Genetic alterations in genes of key cellular signaling 
pathways, particularly mitogen activated protein kinase 
(MAPK) and phosphatidylinositol-3-kinase (PI3K) sign-
aling pathways are the main genetic mechanisms of thy-
roid carcinogenesis [5, 6].
PTC is the most common subtype of thyroid can-
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mutation is the most prevalent genetic alteration in 
PTC (~45  %) [5]. This transversion mutation results in 
thymine-to-adenine (T  >  A) change at nucleotide posi-
tion 1799 (T1799A) substituting valine by glutamic acid 
at amino acid position 600 (V600E). When present, this 
mutation results in constitutive activation of the BRAF 
protein with consequent activation of the downstream 
mediators [5, 7, 8].
A large number of studies from different ethnic back-
grounds reported BRAFV600E mutation in 29–83  % 
of PTC [7]. These studies were mostly undertaken in 
patients with DTC of various ages. To our knowledge, 
no previous study reported BRAFV600E mutation in a 
pure adult population. The relationship of BRAFV600E 
mutation and age of the patient at diagnosis has been 
inconsistent. Some studies showed significant correla-
tion [9, 10] while others didn’t demonstrate such a cor-
relation [11]. We and others have found a much lower 
rate of BRAFV600E mutation in DTC from pediatric and 
adolescent patients [12, 13]. Furthermore, we also found 
a much lower rate of the recently described TERT muta-
tions in pediatric compared to adult DTC [13]. We 
speculated that the adult and pediatric DTCs are likely 
to have different molecular signatures as suggested by 
these findings and also the significantly different clinical 
and pathological phenotype [14–16]. Saudi population 
is highly inbred with high rate of consanguinity [17, 18]. 
Although BRAFV600E is somatic in nature, one may won-
der whether this high rate of consanguinity may have an 
impact on the prevalence of BRAFV600E mutation and 
prevalence of other non-spot BRAF mutations. Although 
BRAFV600E mutation has been previously reported from 
Saudi Arabian population of various ages [19, 20], it has 
not been investigated in purely adult population. In the 
course of this study, we also found a relatively high rate of 
non-hot spot BRAF mutations. Our aim in this study is to 
determine the prevalence of the BRAFV600E mutation and 
other non-conventional exon 15 BRAF mutations in pure 
adult patients (>18 years) with DTC in this highly inbred 
population.
Methods
Tumor samples and DNA extraction
We studied a sample consisting of 204 sporadic DTCs. 
The clinical and pathological data of these patients are 
summarized in Table 1. The only exclusion criterion was 
age at diagnosis of ≤18 years. DTC samples included 114 
(55.9  %) conventional papillary thyroid cancer (CPTC), 
55 (27  %) follicular variant papillary thyroid cancer 
(FVPTC), 29 (14.2  %) tall cell papillary thyroid cancer 
(TC-PTC), 3 (1.5 %) hurthle cell carcinomas (HCC), and 
3 (1.5  %) diffuse sclerosing type papillary thyroid can-
cer (DSC) collected from the pathology Department of 
the King Faisal Specialist Hospital and Research Centre 
(KFSH&RC), Riyadh, Saudi Arabia (Table 1). The patients 
did not have family history of thyroid cancer. Histologi-
cal diagnosis was confirmed by an experienced endocrine 
pathologist (H.A) who also carefully selected the tumor 
samples from paraffin blocks to ensure that tumor tissue 
was dissected for DNA extraction. Slices of 10-micron 
thickness of tumor samples were dissected from forma-
lin fixed and paraffin embedded tissue (FFPT). Genomic 
DNA was extracted from the tumor tissues as previously 
described [21] using the Gentra Puregene DNA extrac-
tion kit (Qiagen, Valencia, CA).
Ethical approval
This study was approved by the Ethical Committee 
and Institutional Review Board of King Faisal Special-
ist Hospital and Research Center, Riyadh, Saudi Arabia 
(RAC-2130015).
PCR amplification and sequencing
Exon 15 of the BRAF gene was PCR amplified using 
genomic DNA from the tumor samples. The forward 
and reverse primers and the PCR conditions were as 
described previously [22]. We limited our search to exon 
15 as the previously described mutations were mostly 
described in this exon. The PCR amplicons were con-
firmed on 2 % agarose gel and directly sequenced using 
Table 1 Clinical and  histopathological characteristic fea-
tures of 204 cases of adult DTC
Characteristics Number/total (percentage)
Median age in years (range) 35.5 (19–75)
Sex female:male (ratio) 154:50
Median tumor size in cm (range) 2.2 (1–12)
Tumor sub-types (%)
Conventional papillary  
thyroid cancer (CPTC)
114 (55.9)
Follicular variant papillary  
thyroid cancer (FV‑PTC)
55 (27)
Tall cell variant papillary  
thyroid cancer (TC‑PTC)
29 (14.2)
Hurthle cell cancer (HCC) 3 (1.5)




Tumor multifocality 97 (47.5)
Extrathyroidal invasion 95 (46.6)
Lymph node metastasis 91 (44.6)
Distant metastasis 15 (7.4)
TNM staging (%)
Stage I/II 160 (78.4)
Stage III/IV 44 (21.6)
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the Big Dye terminator v3.1 cycle sequencing ready 
reaction kit (Applied Biosystems) and by ABI PRISM 
3730X1, genetic analyzer (Applied Biosystems). Iden-
tified mutations were confirmed in both forward and 
reverse directions by an independent PCR amplification 
and sequencing reaction. For the confirmed mutations, 
matched normal tissue samples were further analyzed 
to check whether the mutations are somatic or germline 
in nature. The sequencing results were read against the 
BRAF gene (GeneBank No.: NM_004333.4).
Statistical analysis
Statistical analyses were performed using SPSS (The Sta-
tistical Package for Social Sciences) version 20 software 
(IBM Corp., NY USA). Data were expressed as median 
and range for numerical values and numbers and per-
centages for categorical data. The T test was used to ana-
lyze continuous variables and Fisher exact and χ2 tests 
were used for categorical data. In all analyses, a two-
tailed P < 0.05 was considered statistically significant.
Availability of data and supporting materials
Paraffin embedded tumor tissues, genomic DNAs and 
data of tumor molecular genetics. The SPSS (The Statisti-
cal Package for Social Sciences) version 20 software was 
obtained from IBM Corp., NY USA. The protein mol-
ecules can be downloaded from http://www.rcsb.org/
pdb/home/home.do using the PDB ID and can be viewed 
using SWISS PDB and Jmol viewer downloaded freely 
from http://www.spdbv.vital-it.ch/ and http://www.jmol.
sourceforge.net/, respectively.
Results
Prevalence of BRAF mutation and identification of rare, 
non‑hotspot BRAF mutation in adult DTCs
Of 204 DTCs, 99 samples (48.5  %) harbored a BRAF 
mutation (Table 2). The hotspot BRAFV600E mutation was 
found in 95 cases (46.5 %). As shown in Table 3, four sam-
ples pertaining to 4 unrelated patients harbored other 
non-hotspot BRAF mutations. One sample harbored 
C  >  T transition mutation at nucleotide position 1796 
resulting in a T599I amino acid change. The tumor was 
a follicular variant papillary thyroid cancer (FV-PTC) 
from a female patient. The other sample harbored a very 
rare 3-base insertion mutation at nucleotide position 
1798 resulting in duplication of threonine 599 (T599dup) 
and this mutation was identified in a tumor from a 
44-year old lady with a 3-cm FV-PTC without extrathy-
roidal invasion, lymph node or distant metastases. Two 
samples, one in a 30-year old lady with CPTC without 
extrathyroidal invasion, lymph node or distant metas-
tases and the other was in a 30-year old lady with 1 cm 
FV-PTC without extrathyroidal extension, lymph node 
or distant metastases, harbored an A > G point mutation 
at nucleotide position 1801 resulting in a K601E amino 
acid change (Fig. 1). These mutations were confirmed to 
be somatic in nature as they were absent in matched nor-
mal tissue samples. These three non-hot spot mutations 
have already been recorded in the COSMIC (Catalogue 
of Somatic Mutations in Cancer) database, UK.
Association of BRAFV600E mutation with clinicopathological 
features and outcome of DTC
Patients included in this study were all adults and the 
mean  ±  SD age was 43.5  ±  15  years in patients with 
BRAFV600E mutation and 36.2  ±  13.3  years in patients 
with wild type BRAF (P 0.0001). Extrathyroidal invasion 
was more frequently observed in tumors with BRAFV600E 
mutation occurring in 54 tumors (56.8  %) compared to 
only 41 (39 %) tumors with wild type BRAF (P = 0.017). 
Lymph node metastasis was more commonly found in 
51 tumors (53.7  %) with BRAFV600E mutation compared 
to 40 tumors (38.1  %) with wild type BRAF (P =  0.038). 
Similarly, BRAFV600E mutation was more common in 
higher stage tumors (stage III/IV) occurring in 31 patients 
(32.6 %) compared with only 13 (12.4 %) in the wild type 
BRAF (P  =  0.001). BRAFV600E mutation was not associ-
ated with gender, tumor size, tumor multifocality, dis-
tant-metastasis, and persistent/recurrent disease at 6–12 
months after initial management and at the last follow up 
(Table 4).
Discussion
In this study, we analyzed exclusively a sample of adult 
DTC patients for BRAF mutations as it has been reported 
that adult DTCs harbor higher frequencies of BRAF 
mutations than pediatric DTC [13, 23, 24] and previ-
ous data showed significant differences in the clinical, 
pathological and molecular basis of pediatric compared 
with adult DTCs [15, 16, 25–28]. We report here 48.5 % 
(99/204) of BRAF mutations in adult DTC from Saudi 
Arabia. As expected, the vast majority of the identified 
mutations were the well described mutation, BRAFV600E 
Table 2 Summary of  exon 15 BRAF mutations identified 







CPTC 55 1 56/114 (49.1)
FV‑PTC 13 3 16/55 (29)
TPTC 27 0 27/29 (93.1)
HCC 0 0 0/3 (0)
DSC 0 0 0/3 (0)
95/204 (46.5 %) 4/204 (1.96 %) 99/204 (48.5)
Page 4 of 8Murugan et al. J Transl Med  (2016) 14:204 
(95/204, 46.5  %). In addition, we also found three rare, 
non-hotspot BRAF mutations (T599I, T599dup and 
K601E) in four cases (4/204, 2  %). Although these non-
hot spot mutations were previously described, their rate 
in this study seems higher than expected. Consanguinity 
is common in Saudi Arabia [17, 18] and although these 
mutations are somatic in nature, it is possible that there 
might be a genetic predisposition to their occurrence 
as inheritance of certain SNPs in the DNA repairing 
machinery genes may theoretically predispose to the 
Table 3 Various non-hotspot BRAF mutations identified in four out of 204 cases of adult DTC
F female; FV-PTC follicular variant papillary thyroid cancer; CPTC conventional papillary thyroid cancer
Tumor no Sex Histology Exon Nucleotide Codon Amino acid Mutation Status
AZ 274 F FV‑PTC 15 C1796T ACA‑ATA T599I Missense Heterozygous
AZ 152 F FV‑PTC 15 1798inTAC T599dup Insertion In frame
AZ 40 F CPTC 15 A1801G AAA‑GAA K601E Missense Heterozygous


















Fig. 1 Identification of BRAF mutations in adult differentiated thyroid cancer. a The chromatogram shows a rare, somatic, non‑hotspot, insertion 
mutation of BRAF gene in exon 15 at nucleotide position 1798 [1798insTAC (T599dup)]. b Shows a rare, somatic, non‑hotspot, point mutation of 
BRAF gene in exon 15 at nucleotide position 1796 [C1796T (T599I)]. c A representative sequencing results shows a rare, somatic, non‑hot spot, 
point mutation of BRAF gene in exon 15 at nucleotide position 1801 [A1801G (K601E)] from two independent tumor samples. In all the above 
cases, sequencing results of the matched normal tissue of each sample are shown in the left side of the panel. All the samples were repeated by 
independent PCR reactions with forward and reversed sequencing
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development of BRAF and other driver mutations in 
PTC.
Detailed analyses of the previously reported BRAF 
mutations in PTCs showed that in addition to the most 
common BRAFV600E mutation, many unique and rare 
non-hotspot mutations have been detected in the exon 
15 of the BRAF gene and these mutations have recently 
been compiled in a report [29]. In our study, we found 
three rare, non-hotspot BRAF mutations in four cases. 
In a tumor from a 47-year old female with FV-PTC, 
we found the rare non-hotspot missense T599I muta-
tion. This mutation has also been previously reported in 
a follicular variant [30] and in a solid variant [31] PTC. 
In both cases, the T599I mutation was originally iden-
tified as a concomitant mutation with a complex BRAF 
mutation V600delinsAL (replacement of valine with an 
alanine and a leucine) in the same allele, and VKSRdel 
(deletion of valine 600, lysine 601, serine 602, and argi-
nine 603), respectively [30, 31]. However, we did not find 
any co-existing mutation with the T599I mutation in our 
patient’s tumor sample. Previously reported functional 
analysis of this mutation revealed that the T599I mutant 
had a moderately increased kinase activity but with dra-
matically increased phosphorylation and activation of 
ERK [8]. This phenomenon might be related to the effect 
of dimerization which is likely achieved via complex-
ing with wild-type BRAF and RAF1 [32]. As illustrated 
in Fig.  2, this mutation is located in the core region of 
the kinase domain and more specifically in the activa-
tion loop that is encoded by the nucleotides of the BRAF 
exon 15. Moreover, the rare non-hotspot mutation T599I 
resides in one of the two critical phosphorylation sites 
(T599 and S602) in the activation loop. As BRAF is a ser-
ine/threonine kinase, it has been hypothesized that phos-
phorylation of Threonine 599 and Serine 602 residues 
disturb the hydrophobic interaction of P-loop (phosphate 
binding loop) with the A-loop (activation loop) [8]. 
Therefore, it is likely that phosphorylating either the S/T 
residues would substantially result in destabilization of 
inactive BRAF protein and constitutively switching to 
active conformation. In a previous report from Saudi 
Arabia, deletion of threonine at this position (T599del) 
was described in 1 out of 69 benign follicular adenomas, 
and 1 of 115 PTC harbored an insertion of additional 
threonine at this position (T599dup) [20]. This latter 
mutation was also detected in another patient from our 
series. This mutation was previously described in a pilo-
cytic astrocytoma [33] and in anaplastic thyroid cancer 
(ATC) samples with tall cell like phenotypes [34, 35]. It 
has been demonstrated that the T599dup displays an 
increased kinase activity and enhanced MEK phospho-
rylation followed by ERK activation and potentially com-
parable to those of the hotspot BRAFV600E mutation [33]. 
In addition, this insertion mutation has also been shown 
to transform the NIH3T3 and MCF-10A cells in culture. 
It has been speculated that insertion of an additional 
amino acid at this T599 residue of the protein back-
bone destabilizes the inactive conformation of the kinase 
domain which may result in its conversion to an active 
mutant BRAF [33].
We also identified another rare non-hotspot muta-
tion (K601E) in two tumor samples of adult DTC, one 
from a CPTC and the other from a FV-PTC. This muta-
tion has been well documented in DTC and is considered 
the second most common BRAF mutation in DTC after 
BRAFV600E. Furthermore, it also has been found to be asso-
ciated with tumor cells with histological features of FVPTC 
[10], more specifically in the encapsulated follicular variant 
of PTC. Recently, it has been shown that this K601E muta-
tion may also be found rarely in other sub-types of thyroid 
cancer including follicular thyroid carcinoma (FTC) [36]. 
In the study by Schulten et  al. this mutation was found 
Table 4 Comparison of  clinical and  histopathological characteristics between  patients with  positive and  negative 
BRAFV600E mutation in adult DTCs
* Statistically significant
Characteristics BRAFV600E mutation BRAF wild type P value
(95 cases) (105 cases)
Age mean ± SD (years) 43.5 ± 15 36.2 ± 13.3 0.0001*
Sex (female:male) 71:24 79:26 1.00
Tumor size 3.05 ± 1.97 3.31 ± 2.43 0.42
Tumor multifocality 49 (51.6 %) 48 (45.7 %) 0.49
Extrathyroidal invasion 54 (56.8 %) 41 (39 %) 0.017*
Lymph node metastasis 51 (53.7 %) 40 (38.1 %) 0.038*
Distant metastasis 6 (6.3 %) 9 (8.6 %) 0.74
TNM stage III/IV 31 (32.6 %) 13 (12.4 %) 0.001*
Persistent disease (6–12 months after initial management) 47 (49.5 %) 43 (40.96 %) 0.29
Persistent/recurrent disease (At last follow up) 37 (38.9 %) 30 (28.6 %) 0.16
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in three cases, an FTC, a PTC and a FV-PTC [20]. Tran-
sient transfection mediated functional characterization of 
this mutation in HEK 293T cells showed enhanced kinase 
activity resulting in subsequent strong MEK phosphoryla-
tion and activation of ERK1/2 kinases in the absence of 
TSH [30] suggesting that this is a typical gain-of-function 
mutation and likely to drive cell proliferation and thyroid 
carcinogenesis in a kinase dependent fashion. We found 
that all of these three rare non-hotspot mutations were 
in cases of FV-PTC and the K601E was also found in one 
case of CPTC. Interestingly, the histopathological features 
and the outcome of patients with those mutations were 
favorable. In all cases, the tumor size was relatively small 
(1–3 cm) and there was no evidence of extrathyroidal inva-
sion, lymph node or distant metastases. All patients were in 
remission after the initial management.
Apart from these rare non-hot spot BRAF muta-
tions, BRAFV600E was common in this series of adult 
DTCs. Similar to previous studies, we found a statis-
tically significant association between the BRAFV600E 
mutation and age (P  <  0.0001), extrathyroidal invasion 
(P  =  0.017), lymph node metastasis (P  =  0.038) and 
TNM stage III/IV (P = 0.001) but not with other clinical 
and histopathological features such as gender, tumor 
size, tumor multifocality, distant metastasis, persistent 
and persistent/recurrent disease. This might be due to 
the relatively small sample size. To the best of our knowl-
edge, this study is the first to determine the frequency 
of BRAF mutation exclusively in a pure sample of adult 
DTC patients. The previously reported studies were a 
mixture of adult and pediatric cases [19, 20]. BRAFV600E 
mutation has been detected with a frequency ranging 
between ~30–85 % in classical PTC. On the other hand, 
in case of FVPTC, the frequency ranges between ~0 and 
35  % [7, 11, 37]. The frequency of the BRAF mutations 
identified in our study is comparable to that of the other 
studies in the Middle East region [19, 20, 38].
Conclusions
We have reported the frequency of exon 15 BRAF muta-
tions (48.5  %) in a pure sample of adult DTC patients 
from an ethnically different population with a high rate 
of consanguinity and high rate of thyroid cancer. In addi-
tion to the common occurrence of BRAFV600E mutation, 
we describe a relatively high rate of non-hotspot BRAF 
mutations (T599I, T599dup and K601E). These mutations 
a
b
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Fig. 2 Schematic diagram of the BRAF. a Schematic diagram of the BRAF shows the rare, somatic, non‑hot spot, mutations of BRAF gene in exon 15 
at various nucleotide positions, numbers in the boxes indicate exons and boxes indicate various domains: RBD‑ras binding domain, CRD‑cysteine 
rich domain, KD‑kinase domain, L–G loop, a conserved glycine motif. b A diagram of native modeled structure of BRAF homodimer. Each monomer 
molecule is indicated in different color (red and green). The structure of BRAF protein in complex PDB ID is 4E26. Amino acid residues of rare, non‑
hotspot, somatic mutation identified in adult differentiated thyroid cancer are plotted in BRAF native protein structure using SWISS PDB viewer and 
the mutated residues are shown in sphere shape. c Shows the monomer cartoon diagram of native modeled structure of BRAF kinase domain. The 
structure of BRAF protein kinase domain (monomer) PDB ID is 4WO5. Amino acid residues of rare, non‑hotspot, somatic mutation identified in adult 
differentiated thyroid cancer are plotted in BRAF native protein structure and the molecule is visualized by JSmol
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were detected in 4 out of 204 cases (2 %) of DTC in our 
study. Our results show a high rate and a strong prognos-
tic role of the classical BRAFV600E mutation and also sug-
gest a common occurrence of non-hot spot mutations in 
adult DTC from this highly inbred population.
Abbreviations
DTC: differentiated thyroid cancer; PDTC: poorly differentiated thyroid cancer; 
CPTC: conventional papillary thyroid cancer; FVPTC: follicular variant thyroid 
cancer; TC‑PTC: tall cell papillary thyroid cancer; HCC: hurthle cell carci‑
noma; DSC: diffuse sclerosing type papillary thyroid cancer; FTC: follicular 
thyroid cancer; FFPT: formalin fixed and paraffin embedded tissue; PCR: 
polymerase chain reaction; MAPK: mitogen activated protein kinase; PI3K: 
phosphatidylinositol‑3‑kinase.
Authors’ contributions
AKM and EQ carried out the molecular genetic studies, aligned the sequence, 
analyzed the data and AKM drafted the manuscript. HH carefully selected 
tumor and normal samples and sectioned tissues. HH and YS participated in 
the sequence alignment. AKM and AA conceived of the study, participated 
in its design and coordination. AA directed the whole study, performed the 
statistical analysis, verfied the results and reviewed and edited the manuscript. 
All authors read and approved the final manuscript.
Author details
1 Molecular Endocrinology Section, Department of Molecular Oncology, 
King Faisal Specialist Hospital and Research Center, Research Center (MBC 
03), PO Box 3354, Riyadh 11211, Saudi Arabia. 2 Department of Pathology 
and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, 
Riyadh, Saudi Arabia. 3 Department of Genetics, King Faisal Specialist Hospital 
and Research Center, Riyadh, Saudi Arabia. 4 Department of Medicine, King 
Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by King Abdulaziz City for Science and Technology, 
Riyadh, Saudi Arabia (12‑BIO2952‑20).
Received: 29 April 2016   Accepted: 22 June 2016
References
 1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United 
States, 1973–2002. JAMA. 2006;295:2164–7.
 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA Cancer J Clin. 2011;61:69–90.
 3. Pathology and genetics of tumours of endocrine organs. In: IARC WHO 
classification of tumours. World Health Organization; 2004.
 4. National Cancer Registry. Riyadh: 2007.
 5. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat 
Rev Cancer. 2013;13:184–99.
 6. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid 
cancer. Nat Rev Endocrinol. 2011;7:569–80.
 7. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 
2005;12:245–62.
 8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu‑Duvaz D, Good VM, Jones 
CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation 
of the RAF‑ERK signaling pathway by oncogenic mutations of B‑RAF. Cell. 
2004;116:855–67.
 9. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, 
Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. 
BRAF mutations in thyroid tumors are restricted to papillary carcinomas 
and anaplastic or poorly differentiated carcinomas arising from papillary 
carcinomas. J Clin Endocrinol Metab. 2003;88:399–404.
 10. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, 
Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle‑
Teijeiro J, Sobrinho‑Simões M. Type and prevalence of BRAF mutations 
are closely associated with papillary thyroid carcinoma histotype and 
patients’ age but not with tumour aggressiveness. Virchows Arch. 
2005;446:589–95.
 11. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana 
P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck‑Peccoz P, Pacini 
F, Pinchera A, Santeusanio F, Elisei R. Correlation between B‑RAFV600E 
mutation and clinico‑pathologic parameters in papillary thyroid carci‑
noma: data from a multicentric Italian study and review of the literature. 
Endocr Relat Cancer. 2006;13:455–64.
 12. Eszlinger M, Niedziela M, Typlt E, Jaeschke H, Huth S, Schaarschmidt J, 
Aigner T, Trejster E, Krohn K, Bösenberg E, Paschke R. Somatic mutations 
in 33 benign and malignant hot thyroid nodules in children and adoles‑
cents. Mol Cell Endocrinol. 2014;393:39–45.
 13. Alzahrani AS, Qasem E, Murugan AK, Al‑Hindi HN, Alkhafaji DM, 
Almohanna M, Xing M, Alhomaidah D, Alswailem M. Uncommon TERT 
promoter mutations in pediatric thyroid cancer. Thyroid. 2015;26:235–41.
 14. Alzahrani AS, Alkhafaji D, Tuli M, Al‑Hindi H, Sadiq BB. Comparison of dif‑
ferentiated thyroid cancer in children and adolescents (≤20 years) with 
young adults. Clin Endocrinol (Oxf ). 2015. doi:10.1111/cen.12845.
 15. Kim SS, Kim SJ, Kim IJ, Kim BH, Jeon YK, Kim YK. Comparison of clinical 
outcomes in differentiated thyroid carcinoma between children and 
young adult patients. Clin Nucl Med. 2012;37:850–3.
 16. Sassolas G, Hafdi‑Nejjari Z, Casagranda L, Berger C, Bournaud C, 
Decaussin‑Petrucci M, Berger N, Borson‑Chazot F. Thyroid cancers in 
children, adolescents, and young adults with and without a history of 
childhood exposure to therapeutic radiation for other cancers. Thyroid. 
2013;23:805–10.
 17. El‑Mouzan MI, Al‑Salloum AA, Al‑Herbish AS, Qurachi MM, Al‑Omar AA. 
Regional variations in the prevalence of consanguinity in Saudi Arabia. 
Saudi Med J. 2007;28:1881–4.
 18. Kari JA, Bockenhauer D, Stanescu H, Gari M, Kleta R, Singh AK. Con‑
sanguinity in Saudi Arabia: a unique opportunity for pediatric kidney 
research. Am J Kidney Dis. 2014;63:304–10.
 19. Abubaker J, Jehan Z, Bavi P, Sultana M, Al‑Harbi S, Ibrahim M, Al‑Nuaim A, 
Ahmed M, Amin T, Al‑Fehaily M, Al‑Sanea O, Al‑Dayel F, Uddin S, Al‑Kuraya 
KS. Clinicopathological analysis of papillary thyroid cancer with PIK3CA 
alterations in a Middle Eastern population. J Clin Endocrinol Metab. 
2008;93:611–8.
 20. Schulten HJ, Salama S, Al‑Mansouri Z, Alotibi R, Al‑Ghamdi K, Al‑Hamour 
OA, Sayadi H, Al‑Aradati H, Al‑Johari A, Huwait E, Gari M, Al‑Qahtani MH, 
Al‑Maghrabi J, Sayadi H. BRAF mutations in thyroid tumors from an ethni‑
cally diverse group. Hered Cancer Clin Pract. 2012;10:10.
 21. Murugan AK, Humudh EA, Qasem E, Al‑Hindi H, Almohanna M, Hassan 
ZK, Alzahrani AS. Absence of somatic mutations of the mTOR gene in 
differentiated thyroid cancer. Meta Gene. 2015;6:69–71.
 22. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, 
Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. 
J Natl Cancer Inst. 2003;95:625–7.
 23. Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. BRAF V600E 
does not predict aggressive features of pediatric papillary thyroid carci‑
noma. Laryngoscope. 2014;124:E389–93.
 24. Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T, Grigsby PW. 
BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood 
Cancer. 2014;61:1168–72.
 25. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti 
JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, 
Thompson GB, Yamashita S. The American thyroid association guide‑
lines task force on pediatric thyroid cancer. Management guidelines for 
children with thyroid nodules and differentiated thyroid cancer. Thyroid. 
2015;25:716–59.
 26. Rivera G, Lugo‑Vicente H. Thyroid cancer in children. Bol Asoc Med P R. 
2014;106:48–54.
 27. Vaisman F, Corbo R, Vaisman M. Thyroid carcinoma in children 
and adolescents‑systematic review of the literature. J Thyroid Res. 
2011;2011:845362.
Page 8 of 8Murugan et al. J Transl Med  (2016) 14:204 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 28. Wang JT, Huang R, Kuang AR. Comparison of presentation and clinical 
outcome between children and young adults with differentiated thyroid 
cancer. Asian Pac J Cancer Prev. 2014;15:7271–5.
 29. Matsuse M, Mitsutake N, Tanimura S, Ogi T, Nishihara E, Hirokawa M, Fuzi‑
wara CS, Saenko VA, Suzuki K, Miyauchi A, Yamashita S. Functional char‑
acterization of the novel BRAF complex mutation, BRAF(V600delinsYM), 
identified in papillary thyroid carcinoma. Int J Cancer. 2013;132:738–43.
 30. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, San‑
toro M, Basolo F. Functional characterization of the novel T599I‑VKSRdel 
BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin 
Endocrinol Metab. 2008;93:4398–402.
 31. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, 
Nikiforov Y. A novel complex BRAF mutation detected in a solid variant of 
papillary thyroid carcinoma. Endocr Pathol. 2009;20:122–6.
 32. Roskoski R Jr. RAF protein‑serine/threonine kinases: structure and regula‑
tion. Biochem Biophys Res Commun. 2010;399:313–7.
 33. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke 
M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T. Functional 
characterization of a BRAF insertion mutant associated with pilocytic 
astrocytoma. Int J Cancer. 2011;129:2297–303.
 34. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Onco‑
genic RAF1 rearrangement and a novel BRAF mutation as alternatives 
to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic 
astrocytoma. Oncogene. 2009;28:2119–23.
 35. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Tous‑
saint B, Klein M, Vignaud JM, Bressenot A. BRAF, p53 and SOX2 in anaplas‑
tic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology. 
2011;43:447–52.
 36. Afkhami M, Karunamurthy A, Chiosea S, Nikiforova MN, Seethala R, 
Nikiforov YE, Coyne C. Histopathologic and clinical characterization of 
thyroid tumors carrying the BRAF mutation. Thyroid. 2015. doi:10.1089/
thy.2015.0227.
 37. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle‑
Teijeiro J, Garcia‑Rostan G. BRAF mutation associated with other genetic 
events identifies a subset of aggressive papillary thyroid carcinoma. Clin 
Endocrinol (Oxf ). 2008;68:618–34.
 38. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda 
M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R. 
BRAF(V600E) mutation and the biology of papillary thyroid cancer. 
Endocr Relat Cancer. 2008;15:191–205.
